| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Christopher Giuliano | |
| Krystal K Haase | |||
| Ronald Hall | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Nephrotoxicity of vancomycin, alone and with an aminoglycoside | Q28335291 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Vancomycin-induced immune thrombocytopenia. | Q33374388 | ||
| Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection | Q33979426 | ||
| Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit | Q33979524 | ||
| Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study | Q33982863 | ||
| Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y | Q34426508 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. | Q34510414 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q34910366 | ||
| Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients | Q34991274 | ||
| Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections | Q35123139 | ||
| Vancomycin pharmacokinetics in burn patients and intravenous drug abusers | Q35253581 | ||
| Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid | Q35623055 | ||
| Vancomycin pharmacokinetics in normal and morbidly obese subjects | Q35675005 | ||
| Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients | Q35808723 | ||
| Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique | Q35809992 | ||
| Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): review of 10 cases | Q36105060 | ||
| Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy | Q36376712 | ||
| Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia | Q36428418 | ||
| Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity | Q36538707 | ||
| Evaluation of vancomycin for therapy of adult pneumococcal meningitis | Q36757364 | ||
| The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus | Q36779557 | ||
| Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning | Q36863642 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Multicenter evaluation of vancomycin dosing: emphasis on obesity. | Q36961341 | ||
| Vancomycin ototoxicity: a reevaluation in an era of increasing doses | Q37072057 | ||
| Endocarditis caused by Staphylococcus aureus: A reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. | Q37437092 | ||
| Vancomycin ototoxicity and nephrotoxicity. A review | Q39542494 | ||
| Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices | Q39771366 | ||
| Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions | Q39815643 | ||
| Vancomycin concentrations in infected and noninfected human bone | Q39832249 | ||
| Population pharmacokinetic parameters of vancomycin in critically ill patients | Q40290397 | ||
| Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus | Q41873909 | ||
| Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus | Q42072065 | ||
| Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model | Q42111799 | ||
| Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used | Q43202070 | ||
| Necessity of a loading dose when using vancomycin in critically ill patients | Q43519089 | ||
| Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? | Q44379429 | ||
| Penetration of vancomycin into human lung tissue | Q44470518 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections | Q46431265 | ||
| Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia | Q46434907 | ||
| Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients | Q46607614 | ||
| Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks | Q46788735 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia | Q46933141 | ||
| Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. | Q47368802 | ||
| Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. | Q53013240 | ||
| Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. | Q53945242 | ||
| Pulmonary disposition of vancomycin in critically ill patients. | Q54374101 | ||
| Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery | Q68992674 | ||
| Vancomycin dosing in morbidly obese patients | Q77708439 | ||
| Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients | Q79429283 | ||
| Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study | Q79436937 | ||
| Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus | Q80363319 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia | Q80783502 | ||
| Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage | Q93571562 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| vancomycin | Q424027 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 95-106 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections | |
| P478 | volume | 8 |
| Q89287100 | Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore |
| Q26770913 | Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis |
| Q41208737 | Comment on "Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction". |
| Q38907793 | Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). |
| Q37125081 | Effects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patients |
| Q47142517 | Interventions Targeting the Prescribing and Monitoring of Vancomycin for Hospitalized Patients: A Systematic Review Protocol. |
| Q59125936 | Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review with meta-analysis |
| Q36175569 | Intrathoracic irrigation with arbekacin for methicillin-resistant Staphylococcus aureus empyema following lung resection |
| Q37673485 | Is therapeutic drug monitoring of teicoplanin useful? |
| Q37120168 | New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients |
| Q49392078 | Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: impact on clinical behavior and therapeutic drug monitoring outcomes. |
| Q40321062 | Pharmacokinetics of vancomycin and dosing recommendations for trauma patients |
| Q33949459 | Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety. |
| Q43378543 | Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy. |
| Q105704597 | Synthesis of Aib- and Phe(2Me)-Containing Cyclopentapeptides |
| Q37366784 | The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia |
| Q48575528 | Vancomycin MICs of the resistant mutants of S. aureus ATCC43300 vary based on the susceptibility test methods used |
| Q35004943 | Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens |
| Q38258649 | Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. |
| Q40526316 | Vancomycin serum trough concentration vs. clinical outcome in patients with gram-positive infection: a retrospective analysis. |
Search more.